Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars
Competitor Analysis: Complement C5 Inhibitors 2017 Biosuperiors & Biosimilars
This Competitive Intelligence report about Complement C5 Inhibitors 2017 Biosuperiors & Biosimilars provides a competitor evaluation in the field of mainly recombinant antibodies, but also proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5a receptor as of March 2017.
With annual sales of nearly US$ 3 bln in 2016, Soliris from Alexion Pharmaceuticals has set the stage for next generation biosuperiors as well as biosimilars of a commercially successful and clinically effective treatment of complement C5 mediated diseases. New treatment modalities in development aim at improving the mode and frequency of administration as well as the scope of indications. Players in the field not only include small and medium biotech, but also Big Pharmas
The report includes a compilation of currently active projects in research and development of inhibitors of complement C5 or antagonists of the C5a recepotr. In addition, the report lists company-specific R&D pipelines of C5 inhibitors. Competitor projects are listed in atabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence report about Complement C5 Inhibitors 2017 Biosuperiors & Biosimilars provides a competitor evaluation in the field of mainly recombinant antibodies, but also proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5a receptor as of March 2017.
With annual sales of nearly US$ 3 bln in 2016, Soliris from Alexion Pharmaceuticals has set the stage for next generation biosuperiors as well as biosimilars of a commercially successful and clinically effective treatment of complement C5 mediated diseases. New treatment modalities in development aim at improving the mode and frequency of administration as well as the scope of indications. Players in the field not only include small and medium biotech, but also Big Pharmas
The report includes a compilation of currently active projects in research and development of inhibitors of complement C5 or antagonists of the C5a recepotr. In addition, the report lists company-specific R&D pipelines of C5 inhibitors. Competitor projects are listed in atabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Soliris Pipeline
Soliris Biosimilars
Novel Complement C5 Inhibitors
Complement C5a Receptor Antagonist
Corporate C5 Inhibitor R&D Pipelines
Soliris Biosimilars
Novel Complement C5 Inhibitors
Complement C5a Receptor Antagonist
Corporate C5 Inhibitor R&D Pipelines
